Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults

References

• Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, Sievert DM.. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011-2014. Infect Control Hosp Epidemiol. 2016;37:1288–1301. doi:10.1017/ice.2016.174.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labor and Welfare, Japan Nosocomial Infections Surveillance (JANIS) Clinical Laboratory Division open report 2016. https://janis.mhlw.go.jp/english/report/open_report/2016/3/1/ken_Open_Report_Eng_201600_clsi2012.pdf ( accessed 20 February 2018).
   Google Scholar
• Ministry of Health, Labor and Welfare, Japan Nosocomial Infections Surveillance (JANIS) Antimicrobial-Resistant Bacterial Infection Division open report 2016. https://janis.mhlw.go.jp/report/open_report/2016/3/2/zen_Open_Report_201600.pdf ( accessed 20 February 2018).
   Google Scholar
• Uematsu H, Yamashita K, Kunisawa S, Fushimi K, Imanaka Y. Estimating the disease burden of methicillin-resistant Staphylococcus aureus in Japan: retrospective database study of Japanese hospitals. PLoS One. 2017;12:e0179767. doi:10.1371/journal.pone.0179767.
   PubMed Web of Science ®Google Scholar
• Lenz AM, Fairweather M, Cheadle WG. Resistance profiles in surgical-site infection. Future Microbiol. 2008; 3:453–462. doi:10.2217/17460913.3.4.453.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour and Welfare, Japan Nosocomial Infections Surveillance (JANIS) Surgical Site Infection open report 2016. https://janis.mhlw.go.jp/report/ssi.html ( accessed 20 February 2018).
   Google Scholar
• Takesue Y, Kusachi S, Mikamo H, Sato J, Watanabe A, Kiyota H, Iwata S, Kaku M, Hanaki H, Sumiyama Y, et al. Antimicrobial susceptibility of pathogens isolated from surgical site infections in Japan: comparison of data from nationwide surveillance studies conducted in 2010 and 2014-2015. J Infect Chemother. 2017;23:339–348. doi:10.1016/j.jiac.2017.03.010.
   PubMed Web of Science ®Google Scholar
• Nagao M. A multicentre analysis of epidemiology of the nosocomial bloodstream infections in Japanese university hospitals. Clin Microbiol Infect. 2013; 19:852–858. doi:10.1111/1469-0691.12083.
   PubMed Web of Science ®Google Scholar
• Mohamed N, Wang MY, Le Huec JC, Liljenqvist U, Scully IL, Baber J, Begier E, Jansen KU, Gurtman A, Anderson AS. Vaccine development to prevent Staphylococcus aureus surgical-site infections. Br J Surg. 2017;104:e41–e54. doi:10.1002/bjs.10454.
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr., Creech CB, Sheldon EA, Seiden DJ, Kankam MK, Baber J, Zito E, Hubler R, Eiden J, Severs JM, et al. Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): results from a first-in-human randomised, placebo-controlled phase 1/2 study. Vaccine. 2017;35:375–384. doi:10.1016/j.vaccine.2016.11.010.
   PubMed Web of Science ®Google Scholar
• Creech CB, Frenck RW Jr., Sheldon EA, Seiden DJ, Kankam MK, Zito ET, Girgenti D, Severs JM, Immermann FW, McNeil LK, et al. Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: results of a randomised trial. Vaccine. 2017;35:385–394. doi:10.1016/j.vaccine. 2016.11.032.
   PubMed Web of Science ®Google Scholar
• Begier E, Seiden DJ, Patton M, Zito E, Severs J, Cooper D, Eiden J, Gruber WC, Jansen KU, Anderson AS, et al. SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. Vaccine. 2017;35:1132–1139. doi:10.1016/j.vaccine. 2017.01.024.
   PubMed Web of Science ®Google Scholar
• Frenck R, Creech CB, Fiquet A, Feldman R, Kankam M, Pathirana S, Baber J, Radley D, Cooper D, Eiden J, et al. Persistence of immune responses through 36 months after vaccination with a novel Staphylococcus aureus 4-antigen vaccine (SA4Ag). Vienna (Austria): 27th European Congress of Clinical Microbiology and Infectious Diseases. 2017.
   Google Scholar
• Nanra JS, Buitrago SM, Crawford S, Ng J, Fink PS, Hawkins J, Scully IL, McNeil LK, Aste-Amezaga JM, Cooper D, et al. Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother. 2013;9:480–487.
   PubMed Web of Science ®Google Scholar
• Scully IL, Timofeyeva Y, Keeney D, Matsuka YV, Severina E, McNeil LK, Nanra J, Hu G, Liberator PA, Jansen KU, et al. Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection. Vaccine. 2015;33:5452–5457. doi:10.1016/j.vaccine.2015.08.029.
   PubMed Web of Science ®Google Scholar
• Anderson AS, Scully IL, Timofeyeva Y, Murphy E, McNeil LK, Mininni T, Nunez L, Carriere M, Singer C, Dilts DA, et al. Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. Aureus and Staphylococcus Epidermidis. J Infect Dis. 2012;205:1688–1696. doi:10.1093/infdis/jis272.
   PubMed Web of Science ®Google Scholar
• Nissen M, Marshall H, Richmond P, Shakib S, Jiang Q, Cooper D, Rill D, Baber J, Eiden J, Gruber W, et al. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Vaccine. 2015;33:1846–1854. doi:10.1016/j.vaccine.2015.02.024.
   PubMed Web of Science ®Google Scholar
• Marshall H, Nissen M, Richmond P, Shakib S, Jiang Q, Cooper D, Rill D, Baber J, Eiden J, Gruber WC, et al. Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study. J Infect. 2016;73:437–454. doi:10.1016/j.jinf.2016.08.004.
   PubMed Web of Science ®Google Scholar
• Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA. 2013;309:1368–1378. doi:10.1001/jama.2013.3010.
   PubMed Web of Science ®Google Scholar
• Fattom A, Matalon A, Buerkert J, Taylor K, Damaso S, Boutriau D. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study. Hum Vaccin Immunother. 2015;11:632–641. doi:10.4161/hv.34414.
   PubMed Web of Science ®Google Scholar
• Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346:491–496. doi:10.1056/NEJMoa011297.
   PubMed Web of Science ®Google Scholar
• Kaye KS, Schmit K, Pieper C, Sloane R, Caughlan KF, Sexton DJ, Schmader KE. The effect of increasing age on the risk of surgical site infection. J Infect Dis. 2005;191:1056–1062. doi:10.1086/428626.
   PubMed Web of Science ®Google Scholar
• Kumar R, Burns EA. Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev Vaccines. 2008;7:467–479. doi:10.1586/14760584.7.4.467.
   PubMed Web of Science ®Google Scholar
• Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, Vernachio JH, Severina E, Girgenti D, Jansen KU, et al. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. Clin Vaccine Immunol. 2012;19:1641–1650. doi:10.1128/CVI.00354-12.
   PubMed Web of Science ®Google Scholar
• Rozemeijer W, Fink P, Rojas E, Jones CH, Pavliakova D, Giardina P, Murphy E, Liberator P, Jiang Q, Girgenti D, et al. Evaluation of approaches to monitor Staphylococcus aureus virulence factor expression during human disease. PLoS One. 2015;10:e0116945. doi:10.1371/journal.pone.0116945.
   PubMed Web of Science ®Google Scholar